All articles by Cyrus Fan
Cyrus Fan
First 10 drugs for Medicare price negotiation may see minimal commercial impact
Manufacturers of the selected drugs must sign an agreement with the Centers for Medicare and Medicaid Services to participate in drug price negotiations by 1 October 2023.
Minimal impact expected for first ten drugs released for Medicare price negotiation
The Inflation Reduction Act aims to generate $25bn in drug cost savings for the US Government over the next eight years and reduce Part D out-of-pocket (OOP) costs for Medicare beneficiaries.
House Democrats unveil new legislation that expands the Inflation Reduction Act
Any successful legislation that builds off the Inflation Reduction Act could signal a paradigm shift in US drug pricing.
Comparison of Humira biosimilars in the US and Europe
The US biosimilars market is notably underdeveloped and biosimilar entry in the US has been difficult, consistently lagging behind Europe.
US midterm election results have multiple implications for the pharma industry
The US midterm election results will have important implications for the pharma and healthcare industries over the next two years.
New Covid-19 antivirals priced reasonably according to ICER
ICER’s assessment is extremely unusual, since only 10% of reviewed drugs fell within ICER’s cost-effectiveness threshold, as per a GlobalData analysis.